Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Benign Prostatic Hyperplasia: full-pipeline trial registry
10 of 30 indexed Benign Prostatic Hyperplasia trials are currently recruiting.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 10 currently recruiting · #519 of 28,707 conditions by registered trial count
Benign Prostatic Hyperplasia: 30 US clinical trials tracked, 10 recruiting.
Benign Prostatic Hyperplasia is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Urotronic, running 3 of these trials.
Enrollment posture brief
Registry condition benign-prostatic-hyperplasia
OPEN 10 | RECR 33% | LATE 4 | EARLY 6 | RANK #519 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Benign Prostatic Hyperplasia lists 10 open slots (33% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Benign Prostatic Hyperplasia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Benign Prostatic Hyperplasia is recruiting below its size-band peers.
10 of 30 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Benign Prostatic Hyperplasia trials is spread across many organizations.
Urotronic accounts for 3 of 30 trials (10%). 25 distinct sponsors appear on at least one study for this condition label.
-
Typical Benign Prostatic Hyperplasia enrolment sits around 150 participants.
Median target enrolment is 150 among the 30 trials that report a genuine target (sentinel values excluded). 10 of those (33.3%) plan for fewer than 100 participants.
-
Benign Prostatic Hyperplasia research is mostly interventional.
24 interventional and 6 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
BPH Global Registry
Société Internationale d'Urologie
NCT05543200
Customized TULSA-PRO Ablation Registry
Profound Medical
NCT05001477
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
Urotronic
NCT06560476
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
Northwestern University
NCT05898932
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
Rivermark Medical
NCT06849258
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Axonics
NCT06511141
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Beth Israel Deaconess Medical Center
NCT04288427
Ambulatory Long Length URodynamics Evaluation
Bright Uro
NCT07425015
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
Urotronic
NCT06312722
PRescription Exercise for Older Men With Urinary Disease
University of California, San Francisco
NCT06225479
Laser Prostatectomy Database and Registry
Indiana Kidney Stone Institute
NCT00159406
Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath
Prodeon Medical
NCT05400980
Optilume™ BPH Catheter System in Men With Symptomatic BPH
Urotronic
NCT04131907
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
PROCEPT BioRobotics
NCT06051942
Comparing UroLift Experience Against Rezūm
NeoTract
NCT04338776
Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate
University of Miami
NCT05155891
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
NCT04879940
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
Watson Pharmaceuticals
NCT00224133
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
Eli Lilly and Company
NCT00827242
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
Eli Lilly and Company
NCT00848081
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
NeoTract
NCT01294150
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Eli Lilly and Company
NCT00386009
A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization
American Medical Systems
NCT00465101
Botulinum Toxin Injection for the Management of BPH
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00451191
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
Terumo Medical Corporation
NCT04272216
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
Allergan
NCT00894517
A Self-Administered Maneuver to Relieve Symptoms Suggestive of Benign Prostatic Hyperplasia
Kaiser Permanente
NCT01387893
Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
University of Minnesota
NCT02930889
A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00645034
Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Light Sciences Oncology
NCT00709488
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Benign Prostatic Hyperplasia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Benign Prostatic Hyperplasia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Benign Prostatic Hyperplasia page
30 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Benign Prostatic Hyperplasia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Urotronic sponsors the most Benign Prostatic Hyperplasia trials on record, review their full trial history before evaluating a specific study. See Urotronic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Benign Prostatic Hyperplasia condition card totals 30 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.